Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exclusive-Toshiba's No.2 shareholder calls for immediate resignation of board chair, 3 directors

06/12/2021 | 11:38pm EDT
FILE PHOTO: The logo of Toshiba is seen as a shareholder arrives at an extraordinary shareholders meeting in Chiba

TOKYO (Reuters) -Toshiba Corp's second-biggest shareholder on Sunday demanded the board chairman and three other directors immediately resign after an investigation found the company had colluded with the Japanese government to pressure foreign investors.

The letter, seen by Reuters, is from 3D Investment Partners, which owns a 7.2% stake in Toshiba. It was sent to the four on Sunday, according to people with direct knowledge of the process.

It is likely to heighten scrutiny into governance at Toshiba, a renowned industrial conglomerate in crisis sparked by Thursday's report. The shareholder-commissioned report marked an explosive turn in a long battle between the Japanese company's management and foreign shareholders.

In addition to 3D, these shareholders include activist investors and Harvard University's endowment fund.

The revelations in the report "are deeply troubling and represent one of the most prominent and shocking corporate governance failures among large public companies anywhere in the world in the last decade," the 3D letter says.

The letter, addressed to board chair Osamu Nagayama and three current audit committee members, describes Nagayama as "ultimately responsible for Toshiba's recent governance failures, including the flawed internal investigation and the board's determination to oppose an outside, independent investigation."

"It is also troubling that you have been silent about the investigative report and have failed to accept responsibility for the misconduct that occurred under your oversight as chair of the board," the letter says.

Toshiba declined to comment on the letter, telling Reuters in a statement it was "carefully reviewing the content of the investigation report and plans to announce its comments towards this investigation result after the review."

The company was holding an emergency meeting on Sunday to discuss reassigning the candidates for three key board committees ahead of a June 25 shareholder meeting. Major shareholder advisory firms recommended against some of the candidates, including the four addressed in the 3D letter.

Four independent directors, all non-Japanese, have said in a sign of revolt that they were no longer in support of the full slate of director candidates nominated by Toshiba.

(Reporting by Makiko Yamazaki; Editing by William Mallard)

By Makiko Yamazaki


ę Reuters 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD.
08/03PRESS RELEASE : US FDA grants Priority Review to Roche's Tecentriq as adjuvant t..
DJ
08/02CHUGAI PHARMACEUTICAL : Launches FoundationOne Liquid CDx Cancer Genomic Profile..
PU
07/30CHUGAI PHARMACEUTICAL : Continues to be Listed for All ESG Indices Selected by G..
PU
07/29PRESS RELEASE : FDA accepts application for -2-
DJ
07/29PRESS RELEASE : Data for Roche's Evrysdi(R) -2-
DJ
07/28CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
07/26Chugai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Half E..
CI
07/26Chugai Pharmaceutical Co., Ltd. Provides Earnings Guidance for the First Half..
CI
07/26Chugai Pharmaceutical Co., Ltd. Provides Year-End Dividend Guidance for the F..
CI
07/26CHUGAI PHARMACEUTICAL : CONSOLIDATED FINANCIAL STATEMENTS (IFRS)(Non-Audited)(fo..
PU
More news
Financials
Sales 2021 848 B 7 769 M 7 769 M
Net income 2021 254 B 2 323 M 2 323 M
Net cash 2021 504 B 4 614 M 4 614 M
P/E ratio 2021 26,0x
Yield 2021 1,56%
Capitalization 6 583 B 60 351 M 60 291 M
EV / Sales 2021 7,17x
EV / Sales 2022 7,08x
Nbr of Employees 7 555
Free-Float 37,7%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 4 004,00 JPY
Average target price 4 670,00 JPY
Spread / Average Target 16,6%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-27.24%60 351
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
ELI LILLY AND COMPANY51.62%232 701
NOVARTIS AG-0.20%224 638